Structured Guidance for Care Delivery May Result in Better Counselling for Patients With Breast Cancer

Article

Nurse Navigator Janeen Bazan, RN, OCN, BSN, talks about the 4R Care Sequence® and its impact on the care of patients with breast cancer at the 2021 Oncology Nursing Society Annual Congress.

According to a poster presentation at the recent 2021 Oncology Nursing Society (ONS) Annual Congress, breast cancer care may benefit from guidance in a new care delivery model.

The 4R Care Sequence® is a one-page, multimodality, personalized care project plan that is used by multidisciplinary teams to plan and deliver care. The 4 Rs in the title represent the right information, care, patient, and time. It incorporates recommendations for patient-centric care pathway plans from the Institute of Medicine, Medicare’s Oncology Care Model and National Comprehensive Cancer Network guidelines, which include multi-modality planning from diagnosis to survivorship that specifies the clinical team, identification of therapy, and adverse effects and supportive care.

“The 4R model provides a roadmap for the patient and also for the patient’s care team,” said Janeen Bazan, RN, OCN, BSN, lead author of the poster and an oncology nurse navigator from Advocate Sherman Hospital, during the presentation. “It’s very helpful in time management for the patient.”

To understand how the 4R Care Sequence® plans impacted care, investigators surveyed 77 patients with stage 0 to 3 breast cancer from September 2019 to August 2020 at Advocate Sherman Hospital. Of the patients, 28 received 4R Care Sequences® and 49 received a baseline control model.

A survey given to all patients asked whether or not the patients’ care provider instructed them to do certain activities. The investigators found that all patients who received the 4R Care Sequences® were more likely to have been counseled in 8 areas:

  • Getting an immunization (flu, pneumonia, shingles) before starting cancer treatment (52% of baseline cohort, 70% of 4R cohort)
  • Seeing a dentist before starting cancer treatment (13% of baseline cohort, 33% of 4R cohort)
  • Getting a genetic counseling appointment before surgical decision (39% of baseline cohort, 44% of 4R cohort)
  • Managing weight if over or under weight (16% of baseline cohort, 26% of 4R cohort)
  • Getting a nutritionist consult about how to eat during cancer treatment (15% of baseline cohort, 26% of 4R cohort)
  • Getting emotional support (46% of baseline cohort, 52% of 4R cohort)
  • Keeping up appointments with primary care for routine care (67% of baseline cohort, 75% of 4R cohort)
  • Caring for a chronic disease (43% of baseline cohort, 46% of 4R cohort)

Early results showed that the use of the 4R Care Sequences® improved the referrals of recommended breast cancer care. Due to the small sample size, Bazan reported that the results are not statistically significant, however, the trend is still encouraging. The researchers’ plan to continue using 4R Care Sequences, collecting patient surveys and assessing their impact.

“I’m very excited to look at our next data and share with other programs, and hopefully bring in other cancer types,” Bazan said.

Reference

Bazan J. Early results: Impact of 4R (Right Info / Care / Patient / Time) care sequence plans, provided to patients by oncology nurses, on timing and sequence of guideline recommended care. Presented at: Oncology Nursing Society 46th Annual Congress; April 20, 22, 27, and 29, 2021. ePoster 1567. Accessed May 5, 2021. https://bit.ly/3eXEb0n

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content